Skip to content
Sii urges government to speed up move to increase Covishield stockpile

The Serum Institute of India (SII) urged the government to accelerate the Covishield movement, citing difficulties in producing and planning cold chain space for other vaccines due to the growing stock of its vaccine COVID-19, official sources said on Sunday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at SII, reportedly recently communicated to the Union Department of Health that he has a manufactured stock of 24,89,15,000 doses of Covishield and is increasing daily .

In addition to the Covishield vaccine, the Pune-based company also manufactures and supplies various life-saving vaccines to EPI, UNICEF and various countries, Singh reportedly told the ministry. “To meet our national and global sourcing commitments, we need to plan our production / cold chain / human resources space well in advance. Considering the continued increase in Covishield stock, we are faced with many production / cold chain challenges. space / human resource planning for other life-saving vaccines, ”said an official source quoting Singh in the letter.

“In view of these facts, real difficulties and given that this matter directly concerns the availability of various other vital vaccines in our country and in the world in general, we ask for your kind intervention to accelerate the movement of our Covishield vaccine. nationally and globally, ”Singh reportedly said. The Center has authorized SII to export 50 doses of Lakh from Covishied under the UN-supported COVAX global vaccine sharing program to Nepal, Tajikistan and Mozambique. SII will also export Covishield to Bangladesh under COVAX, an official source said. The Serum Institute will start its export of Covid vaccines under the COVAX program from November 23, and Nepal will receive the first batch of Covishiled on November 24. In October, the government authorized SII to export 10 doses of Covishield lakh, each to Nepal, Myanmar and Bangladesh. as part of the “Vaccin Maitri” program.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.